Literature DB >> 32181745

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study.

Nils-Henning Ness1, Rocco Haase1, Raimar Kern2, Dirk Schriefer1, Benjamin Ettle3, Christian Cornelissen4, Katja Akguen1, Tjalf Ziemssen1.   

Abstract

BACKGROUND: Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments.
OBJECTIVE: The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey.
METHODS: We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses.
RESULTS: In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from -0.006 (convenience) to -0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies.
CONCLUSIONS: The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS. ©Nils-Henning Ness, Rocco Haase, Raimar Kern, Dirk Schriefer, Benjamin Ettle, Christian Cornelissen, Katja Akguen, Tjalf Ziemssen. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 17.03.2020.

Entities:  

Keywords:  multiple sclerosis; patient-reported outcome measures; questionnaire development; resource utilization; validation

Year:  2020        PMID: 32181745     DOI: 10.2196/17921

Source DB:  PubMed          Journal:  J Med Internet Res        ISSN: 1438-8871            Impact factor:   5.428


  6 in total

1.  OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.

Authors:  Tjalf Ziemssen; Stephan Richter; Mathias Mäurer; Mathias Buttmann; Boris Kreusel; Anne-Maria Poehler; Maren Lampl; Ralf A Linker
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

2.  Data Collection in Multiple Sclerosis: The MSDS Approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Isabel Voigt; Rocco Haase
Journal:  Front Neurol       Date:  2020-06-16       Impact factor: 4.003

Review 3.  Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice.

Authors:  Maria Scholz; Rocco Haase; Dirk Schriefer; Isabel Voigt; Tjalf Ziemssen
Journal:  Brain Sci       Date:  2021-02-02

4.  How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in Lower Saxony (MS-PoV).

Authors:  Kathrin Krüger; Lara Marleen Fricke; Elise-Marie Dilger; Annett Thiele; Kristina Schaubert; Dyon Hoekstra; Fedor Heidenreich; Anna Levke Brütt; Jona T Stahmeyer; Alexander Stahmann; Anna-Lena Röper; Klaus-Peter Kubiak; Melissa Hemmerling; Anja Grau; Kerstin Eichstädt; Sabine Behrens; Christian Krauth
Journal:  PLoS One       Date:  2021-11-11       Impact factor: 3.240

5.  Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.

Authors:  Dominik Koeditz; Juergen Frensch; Martin Bierbaum; Nils-Henning Ness; Benjamin Ettle; Umakanth Vudumula; Kapil Gudala; Nicholas Adlard; Santosh Tiwari; Tjalf Ziemssen
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-03-29

6.  Gender disparities in health resource utilization in patients with relapsing-remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients.

Authors:  Dirk Schriefer; Nils-Henning Ness; Rocco Haase; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2020-10-24       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.